https://www.pharmalive.com/wp-content/uploads/2021/06/U.S.-Supreme-Court-rebuffs-AbbVie-appeal-in-patent-fight-involving-AndroGel-drug-Reuters-6-21-21.jpg 503 960 Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Reuters Health2023-03-22 09:21:402023-03-22 09:42:57US FDA declines to approve AbbVie's Parkinson's disease therapy
US FDA declines to approve AbbVie’s Parkinson’s disease therapy
March 22 (Reuters) – AbbVie Inc (ABBV.N) said on Wednesday the U.S. Food and Drug Administration had declined to approve its Parkinson’s disease therapy for adults.
The U.S. health regulator has sought additional information about the delivery pump, which is part of the marketing application, the drugmaker said, and does not want additional efficacy and safety trials.
Abbvie said it plans to resubmit the marketing application as soon as possible.
Parkinson’s disease is a neurological disease that causes unintended or uncontrollable movements, such as shaking, stiffness, and difficulty with balance and coordination.
Reporting by Khushi Mandowara in Bengaluru; Editing by Shinjini Ganguli and Sriraj Kalluvila
Our Standards: The Thomson Reuters Trust Principles.